27 completed. 27 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 27 |
| Phase 2 | 12 | Completed 12 |
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients NS101, Placebo - Seneorineural Deafness, Sudden Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Neuracle Science Co., LTD. | 113 | 2024-02-15 | 2026-11-02 |
| Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss Dexamethasone, Hyaluronic acid - Hearing Loss, Sudden, Hearing Loss, Ototoxic | Phase 1 / Phase 2 | Completed | Seoul National University Hospital | 15 | 2021-07-22 | 2024-10-24 |
| FX-322 in Adults With Severe Sensorineural Hearing Loss FX-322, Placebo - Hearing Loss, Sensorineural, Noise Induced Hearing Loss | Phase 1 | Completed | Frequency Therapeutics | 31 | 2020-11-02 | 2022-02-01 |
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss PIPE-505, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Contineum Therapeutics | 28 | 2020-10-15 | 2025-04-01 |
| FX-322 in Adults With Age-Related Sensorineural Hearing Loss FX-322, placebo - Presbycusis, Hearing Loss, Sensorineural | Phase 1 | Completed | Frequency Therapeutics | 30 | 2020-09-17 | 2022-05-25 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome NPI-001, Placebo - Usher Syndromes | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 49 | 2020-09-03 | 2026-07-01 |
| Auditory Training and Hearing Aid Satisfaction Auditory Brian Training Games/Activities - Hearing Impairment, Sensorineural | Phase 1 | Completed | Washington University School of Medicine | 30 | 2020-09-01 | 2022-09-19 |
| Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment DB-020, Placebo - Ototoxicity | Phase 1 | Completed | Decibel Therapeutics | 22 | 2020-02-21 | 2023-07-06 |
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment OTO-413, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Otonomy, Inc. | 110 | 2019-10-01 | 2022-10-27 |
| Speech Recognition Training in Children With Hearing Loss clEAR auditory training - Hearing Loss | Phase 1 | Completed | Washington University School of Medicine | 34 | 2019-09-01 | 2021-11-10 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| FX-322 in Sensorineural Hearing Loss FX-322, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Frequency Therapeutics | 23 | 2018-07-03 | 2022-11-14 |
| Triamcinolone Levels in Cochlear Perilymph Triamcinolone Acetonide - Cochlear Hearing Loss | Phase 1 | Completed | Christoph Arnoldner | 40 | 2017-10-02 | 2021-09-28 |
| A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome dantrolene sodium - Wolfram Syndrome, Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 21 | 2017-01-01 | 2024-03-13 |
| NAC to Prevent Cisplatin-induced Hearing Loss N-Acetylcysteine - Neuroectodermal Tumors, Primitive, Liver Neoplasms | Phase 1 | Completed | Children's Hospital Los Angeles | 52 | 2016-03-01 | 2023-04-18 |
| Study to Evaluate SPI-1005 in Adults With Meniere's Disease SPI-1005 - Meniere's Disease | Phase 1 / Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 40 | 2015-12-01 | 2026-06-29 |
| Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC HPN-07, NAC, Placebo - Hearing Loss, Sensorineural Hearing Loss | Phase 1 | Completed | Otologic Pharmaceutics, Inc. | 32 | 2014-10-01 | 2015-05-01 |
| Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss CGF166 - Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 22 | 2014-06-23 | 2021-10-08 |
| A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients Auditory Brainstem Implant - Profound Bilateral Deafness Due to, Bilateral Cochlear Aplasia | Phase 1 | Completed | Laurie Eisenberg | 10 | 2014-03-01 | 2025-09-15 |
| Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Ancrod, Saline solution - Hearing Loss, Deafness | Phase 1 / Phase 2 | Completed | Nordmark Arzneimittel GmbH & Co. KG | 31 | 2013-05-01 | 2018-12-21 |
Showing 20 of 27. Sign in to see all of them.
Hearing Loss, Sensorineural (13) · Hearing Loss, Sudden (5) · Deafness (4) · Hearing Loss, Noise-Induced (4) · Meniere Disease (4) · Hearing Loss, Hidden (3) · Tinnitus (2) · Usher Syndromes (2) · Vertigo (2) · Ataxia (1) · Diabetes Mellitus (1) · Ear Diseases (1) · Eye Abnormalities (1) · Eye Diseases (1)
Nervous System Diseases (27) · Neurologic Manifestations (27) · Otorhinolaryngologic Diseases (27) · Pathological Conditions, Signs and Symptoms (27) · Sensation Disorders (27) · Signs and Symptoms (27) · Ear Diseases (26) · Hearing Disorders (26) · Endolymphatic Hydrops (4) · Labyrinth Diseases (4) · Abnormalities, Multiple (3) · Blindness (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)
Acetylcysteine (2) · Hearing Aids (2) · Hyaluronic Acid (2) · ebselen (2) · Ancrod (1) · Auditory Brain Stem Implants (1) · Cell- and Tissue-Based Therapy (1) · Cochlear Implantation (1) · Dantrolene (1) · Dexamethasone (1) · Exercise (1) · Interleukin 1 Receptor Antagonist Protein (1) · Intravitreal Injections (1) · PF-04958242 (1) · Saline Solution (1)
Frequency Therapeutics (3) · Washington University School of Medicine (3) · Otonomy, Inc. (2) · Sound Pharmaceuticals, Incorporated (2) · Andrea Vambutas (1) · Biogen (1) · Children's Hospital Los Angeles (1) · Christoph Arnoldner (1) · Contineum Therapeutics (1) · Decibel Therapeutics (1) · EarLens Corporation (1) · James Baumgartner, MD (1) · Laurie Eisenberg (1) · Nacuity Pharmaceuticals, Inc. (1) · Neuracle Science Co., LTD. (1)
United States (22) · Australia (2) · South Korea (2) · Austria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1)
Carl LeBel, PhD (3) · Andrea Vambutas, MD (1) · Chris A Cardinal, PhD (1) · Eric Wilkinson, MD (1) · Etan Orgel, MD MS (1) · Fumihiko Urano, MD (1) · George Atiee, MD (1) · James Baumgartner, MD (1) · James C. Kisicki, M.D. (1) · John Oghalai (1) · Jonathan Kil, MD (1) · Joseph Park, M.D. (1) · Laurie S. Eisenberg, PhD (1) · Lee Anderson, MD (1) · Martin Canis, MD PhD (1)
PMID 32483557, PMID 20116419, PMID 25133431, PMID 25690605, PMID 25997115, PMID 26366332, PMID 27898605, PMID 29714549, PMID 29718280, PMID 31215818, PMID 34185708, PMID 34591079, PMID 35607935, PMID 37418643, PMID 42479273
2017 (1), 2018 (1), R01DC010075 (1), R21DK113487 (1), R33DC011827 (1), R44DC008499 (1)